

**Full name:** Shelly Melissa Pranić  
(Legal name change from *Campbell* in 2007)

**Contact:**

Department of Public Health  
University of Split School of Medicine  
Šoltanska 2  
21000 Split, Croatia  
Tel.: +385 (0)21 557-817  
E-mail: shelly.pranic@mefst.hr

**Personal information:**

Date of birth: 02/02/1979  
Nationality: American

**Education:**

2011 – 2016 Doctor of Philosophy, University of Split School of Medicine, Croatia  
2003 – 2008 Master of Science in Public Health, Thomas Jefferson University, USA  
1997 – 2001 Bachelor of Arts in Biology, Ithaca College, USA

**Work experience:**

2011 – present Research Assistant, University of Split School of Medicine, Croatia  
2007 – 2010 Laboratory Manager, Mediterranean Institute for Life Sciences (MedILS), Split, Croatia  
2001 – 2007 Laboratory Manager, Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, USA

**Publications:**

10 total publications, refer to complete list at: <http://bib.irb.hr/lista-radova?autor=325286>

*Selected publications:*

**Pranic S**, Marusic A. Changes to registration elements and results in a cohort of Clinicaltrials.gov trials were not reflected in published articles. *J Clin Epidemiol*. 2016; 70:26-37.

Rakovac M, Pedisic Z, **Pranic S**, et al. Sociodemographic and lifestyle correlates of health-related quality of life in Croatian university students. *Appl Res Qual Life*. 2013 Dec;8(4): 493-509.

Pedisic Z, **Pranic S**, et al. Relationship of back and neck pain with quality of life in the Croatian general population. *J Manipulative Physiol Ther*. 2013 Jun; 36(5):267-75.

Glavina T, Mrass D, Dodig T, Glavina G, **Pranić S**, et al. Blood lactate levels in patients receiving first- or second- generation antipsychotics. *Croat Med J*. 2011 Feb;52(1):41-7.

Bix G, Iozzo RA, Woodall B, Burrows M, McQuillan A, **Campbell S**, et al. Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagen-platelet responses via the alpha2beta1-integrin receptor. *Blood*. 2007 May 1; 109(9): 3745-3748.

Goldoni S, Iozzo RA, Kay P, **Campbell S**, et al. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. *Oncogene*. 2007 Jan 18;26(3):368-81.

**Research grants:**

2015 – 2019 Project participant in Professionalism in Health (ProHealth), Croatian Science Foundation grant no. IP-2014-09-7672.  
2016 – 2018 Project participant in New Frontiers of Peer Review (PEERE), European Cooperation in Science and Technology (COST) action grant no. TD1306.  
2010 – 2015 Project participant in Seroepidemiology, hereditary predisposition, and infectious fungal diseases in activities, Ministry of Science, Education and Sports grant no. 216-1080315-0289.  
2001 – 2007 Research project participant in National Institutes of Health Grants RO1 CA39481 and RO1 CA47282